Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159112 | 0.85 | NPC1 (0.41) | NTRK1NTRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6634682 | 0.85 | LMNA (0.53) | NTRK1NTRK2RAB9ASMN1; SMN2BRD4 | |
| SCHEMBL6157976 | 0.83 | NPC1 (0.59) | NTRK1NTRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6158462 | 0.82 | NTRK1 (0.52) | NTRK1NTRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7113060 | 0.82 | RAB9A (0.48) | ITKNTRK1NTRK2NPC1RAB9A | |
| SCHEMBL6982827 | 0.82 | ALDH1A1 (0.53) | NTRK1NTRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6637025 | 0.81 | PAX8 (0.64) | RAB9ASMN1; SMN2BRD4ALDH1A1TP53 | |
| SCHEMBL6159451 | 0.80 | NPC1 (0.42) | NTRK1NTRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6486632 | 0.79 | F2 (0.50) | ITKNTRK1NTRK2NPC1RAB9A | |
| SCHEMBL6475543 | 0.79 | KDM4E (0.48) | ITKNTRK1NTRK2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237877-B1 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1237877-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002062785-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-6407130-B1 | ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM, GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-18 | — | — | US | disclosed |
| WO-2001034572-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | ITK 1616/4885NTRK1 2967/4885NTRK2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.